TSXV:BTI.H - Post by User
Comment by
JDavenporton Dec 16, 2022 3:18pm
112 Views
Post# 35176585
RE:RE:RE:Glioblastoma market US$4.2 billion in 2028
RE:RE:RE:Glioblastoma market US$4.2 billion in 2028In the next 4 to 5 years, poof.
And the minute that Biodexa publicly announces xB3 versions of their drugs, then the market will instantly discount the value of their existing non-xB3 versions. The market will make the correct assumption that the non-xB3 versions are dead and worthless, and that shareholders will have to wait years and years for the new ones.
Not that the market is giving any value to Midatech at all, down over 50%, like Bioasis..
Any more swell deals like this for Bioasis and Midatech and the most that Biodexa will be worth is $2,495.00 for its domain name that it won't need anymore.
jd